Bristol-Myers Squibb’s New Psoriasis Study: What Investors Need to Know

Bristol-Myers Squibb Company ((BMY)) announced an update on their ongoing clinical study.

Study Overview: Bristol-Myers Squibb is conducting a Phase 3 clinical trial titled ‘A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib in Adolescent Participants (12 Years to Less Than 18 Years) With Moderate to Severe Plaque Psoriasis.’ The study aims to assess the effectiveness, safety, and drug levels of Deucravacitinib in adolescents with moderate to severe plaque psoriasis, a condition that significantly impacts quality of life.

Intervention/Treatment: The trial will test Deucravacitinib, a drug designed to treat moderate to severe plaque psoriasis, against a placebo. Deucravacitinib is an active comparator, while the placebo serves as a control to evaluate the drug’s true efficacy.

Study Design: This interventional study is randomized and employs a parallel assignment model. It is double-blind, meaning neither the participants nor the investigators know who receives the actual drug or the placebo. The primary purpose is treatment-focused, aiming to determine the drug’s effectiveness and safety.

Study Timeline: The study is not yet recruiting, with an estimated start date of August 26, 2025. It was first submitted on May 13, 2025, and the latest update was on July 14, 2025. These dates are crucial for tracking the study’s progress and anticipated milestones.

Market Implications: As Bristol-Myers Squibb advances with this study, the potential success of Deucravacitinib could enhance the company’s market position in the dermatology sector. Positive results may boost investor confidence and influence stock performance, especially considering the competitive landscape in psoriasis treatments.

The study is ongoing, with further details accessible on the ClinicalTrials portal.